The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy

Published:2020-04-09 Issue:7 Volume:61 Page:1601-1609
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Tkacz Joseph¹,Garcia Jacob²,Gitlin Mathew³,McMorrow Donna¹,Snyder Sophie³,Bonafede Machaon¹,Chung Karen C.⁴,Maziarz Richard T.⁵

Affiliation:

1. Life Sciences Division, IBM Watson Health, Bethesda, MD, USA;

2. Global Drug Development, Juno Therapeutics, a Celgene company, Seattle, WA, USA;

3. Strategic Health Economics, BluePath Solutions, Los Angeles, CA, USA;

4. Health Economics & Outcomes Research Group, Juno Therapeutics, a Celgene company, Seattle, WA, USA;

5. Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1734592

Reference25 articles.

1. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma

2. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

3. Diffuse large B-cell lymphoma—treatment approaches in the molecular era

4. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

5. Management of relapsed-refractory diffuse large B cell lymphoma

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: A retrospective claims analysis (2015–2020);Journal of Medical Economics;2024-09-10

2. Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma;Journal of Blood Medicine;2024-09

3. Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma;Journal of Medical Economics;2024-05-06

4. Treatment Patterns and Costs Among US Patients With Diffuse Large B-Cell Lymphoma not Treated With 2L Stem Cell Transplantation;Future Oncology;2024-03

5. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma;Blood Reviews;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3